Skip to main content

Sarepta’s surprise FDA approval for rare disease drug excites investors

The Food and Drug Administration’s out-of-the-blue approval of Sarepta Therapeutics’ second Duchenne muscular dystrophy drug sent the company’s stock soaring.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.